Thomas Butler, President & CEO
Biomea Fusion
Menin
is a scaffold protein that acts as a control for the regeneration of insulin-producing beta cells and is also crucial for the growth of certain cancers.
About Menin
This website was designed by Biomea Fusion to help patients with menin-regulated pathologies better understand their disease and help them find potential treatments. Diabetes, cancer, and most other diseases have complex mechanisms. Most diseases occur when the equilibrium of the human body is disturbed, either through the upregulation or downregulation of certain genes, proteins, hormones, and other natural molecules otherwise under control. Menin is one of these crucial proteins. The MEN 1 gene, which is responsible for making menin, was identified in 1997 by two research groups, the National Institute of Health group and the European MEN1 Consortium (Chandrasekharappa et al. 1997)
Biomea Fusion
Biomea derives from the Greek word bios, meaning “life,” and the Latin word mea, meaning “my.” Biomea was founded in 2017 with the goal to help patients safely and effectively beat their cancers. Biomea’s mission is to cure this disease. Biomea uses a targeted approach to directly address a protein which was found to be central to the growth and survival of many cancers, and a critical factor in type 2 diabetes – menin. Biomea uses sophisticated chemistry to selectively and effectively inhibit menin. Biomea’s first innovative medicine is called BMF-219. BMF-219 covalently attaches to menin and inhibits its function. This approach may halt cancer growth. It may also effectively regenerate beta cells in patients with type 2 diabetes. The profile of BMF-219 is compelling. In nonclinical studies, BMF-219 has exerted strong control over menin while maintaining a potentially favorable safety profile. Biomea developed its menin inhibitor covalently in order to form a permanent bond to its target protein menin. This technique offers a number of potential advantages over conventional noncovalent menin inhibitors, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response. Since Biomea’s inception in 2017, the company has built its proprietary FUSION System platform to design and develop a pipeline of novel covalent therapies, such as BMF-219.
We Aim to Cure
Biomea’s management team has significant experience in diabetes and precision oncology in progressing products from early-stage research to clinical trials, and ultimately to regulatory approval and commercialization. Together, the team brings in-house expertise in medicinal chemistry, biology, translational medicine, computational biology and chemistry, in vitro and in vivo pharmacology, biomarker development, and manufacturing. The company has also established internal expertise in clinical development, clinical operations, pharmacovigilance, clinical pharmacology, regulatory, and quality. Biomea exists to serve and support its patients in their battle with serious diseases.